Mainga Hamaluba/Lancet
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.Datoo MS
Dicko A
Tinto H
Ouedraogo JB
Hamaluba M
Olotu A
Beaumont E
Ramos Lopez F
Natama HM
Weston S
Chemba M
Compaore YD
Issiaka D
Salou D
Some AM
Omenda S
Lawrie A
Bejon P
Rao H
Chandramohan D
Roberts R
Bharati S
Stockdale L
Gairola S
Greenwood BM
Ewer KJ
Bradley J
Kulkarni PS
Shaligram U
Hill AVS
R1/Matrix-M Phase 3 Trial Group
Lancet, (2024). 403:533-544
Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.Juan-Giner A
Kimathi D
Grantz KH
Hamaluba M
Kazooba P
Njuguna P
Fall G
Dia M
Bob NS
Monath TP
Barrett AD
Hombach J
Mulogo EM
Ampeire I
Karanja HK
Nyehangane D
Mwanga-Amumpaire J
Cummings DAT
Bejon P
Warimwe GM
Grais RF
Lancet, (2021). 397:119-127
